SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Jasper Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Jasper Therapeutics, Inc. following significant issues related to its drug studies and a substantial stock price drop [2][5]. Group 1: Company Issues - Jasper Therapeutics announced on July 7, 2025, that data from its BEACON Study was compromised due to problems with a specific drug product lot, affecting 10 out of 13 patients [3]. - The same defective lot was also used in the ETESIAN Study, leading to the halt of that study and a pause in asthma development [4]. - The company is implementing cost-cutting measures and potential restructuring to extend its cash runway, contradicting previous assurances of financial stability through Q3 2025 [4]. Group 2: Stock Performance - Following the announcement of the compromised data and halted studies, Jasper's stock price fell by $3.73, or 55.1%, closing at $3.04 per share on July 7, 2025 [5].